z-logo
Premium
Comparison of 60 or 90 mg/m 2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics
Author(s) -
Devillier Raynier,
Bertoli Sarah,
Prébet Thomas,
Huguet Françoise,
Etienne Anne,
Charbonnier Aude,
Rey Jérôme,
Delabesse Eric,
D'Incan Evelyne,
Huynh Anne,
Blaise Didier,
Récher Christian,
Vey Norbert
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23884
Subject(s) - cytogenetics , daunorubicin , myeloid leukemia , leukemia , medicine , myeloid leukaemia , cancer research , biology , genetics , chromosome , gene

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom